Meike H van der Ree1, J Marleen de Vree2, Femke Stelma1, Sophie Willemse3, Marc van der Valk4, Svend Rietdijk5, Richard Molenkamp6, Janke Schinkel6, Ad C van Nuenen7, Ulrich Beuers3, Salah Hadi8, Marten Harbers8, Eva van der Veer9, Kai Liu10, John Grundy10, Amy K Patick10, Adam Pavlicek10, Jacqueline Blem10, Michael Huang10, Paul Grint10, Steven Neben10, Neil W Gibson10, Neeltje A Kootstra7, Hendrik W Reesink11. 1. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands. 2. Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands. 3. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 4. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, Netherlands. 5. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Onze Lieve Vrouwe Gasthuis, Oosterpark, Amsterdam, Netherlands. 6. Department of Medical Microbiology, Clinical Virology Laboratory, Academic Medical Center, Amsterdam, Netherlands. 7. Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands. 8. PRA Health Sciences, Zuidlaren, the Netherlands. 9. DDL Diagnostic Laboratory, Rijswijk, Netherlands. 10. Regulus Therapeutics, San Diego, CA, USA. 11. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands. Electronic address: h.w.reesink@amc.uva.nl.
Abstract
BACKGROUND: miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122, in patients with chronic HCV infection with various genotypes. METHODS: In this randomised, double-blind, placebo-controlled, multicentre, phase 1B study, patients were randomly assigned to RG-101 or placebo (7:1). We enrolled men and postmenopausal or hysterectomised women (aged 18-65 years) with chronic HCV genotype 1, 3, or 4 infection diagnosed at least 24 weeks before screening who were either treatment naive to or relapsed after interferon-α based therapy. Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompensated liver disease, or a history of hepatocellular carcinoma were excluded. Randomisation was done by an independent, unblinded, statistician using the SAS procedure Proc Plan. The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo. Patients were followed up for 8 weeks (all patients) and up to 76 weeks (patients with no viral rebound and excluding those who were randomised to theplacebo group) after randomisation. The primary objective was safety and tolerability of RG-101. This trial was registered with EudraCT, number 2013-002978-49. FINDINGS:Between June 4, 2014, and Oct 27, 2014, we enrolled 32 patients with chronic HCV genotype 1 (n=16), 3 (n=10), or 4 (n=6) infections. In the first cohort, 14 patients were randomly assigned to receive 2 mg/kg RG-101 and two patients were randomly assigned to receive placebo, and in the second cohort, 14 patients were randomly assigned to receive 4 mg/kg RG-101 and two patients were randomly assigned to receive placebo. Overall, 26 of the 28 patients dosed with RG-101 reported at least one treatment-related adverse event. At week 4, the median viral load reduction from baseline was 4·42 (IQR 3·23-5·00) and 5·07 (4·19-5·35) log10 IU/mL in patients dosed with 2 mg/kg RG-101 or 4 mg/kg RG-101. Three patients had undetectable HCV RNA levels 76 weeks after a single dose of RG-101. Viral rebound at or before week 12 was associated with the appearance of resistance associated substitutions in miR-122 binding regions in the 5' UTR of the HCV genome. INTERPRETATION: This study showed that one administration of 2 mg/kg or 4 mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucleotide, was well tolerated and resulted in substantial viral load reduction in all treated patients within 4 weeks, and sustained virological response in three patients for 76 weeks. FUNDING: Regulus Therapeutics, Inc.
RCT Entities:
BACKGROUND:miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122, in patients with chronic HCV infection with various genotypes. METHODS: In this randomised, double-blind, placebo-controlled, multicentre, phase 1B study, patients were randomly assigned to RG-101 or placebo (7:1). We enrolled men and postmenopausal or hysterectomised women (aged 18-65 years) with chronic HCV genotype 1, 3, or 4 infection diagnosed at least 24 weeks before screening who were either treatment naive to or relapsed after interferon-α based therapy. Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompensated liver disease, or a history of hepatocellular carcinoma were excluded. Randomisation was done by an independent, unblinded, statistician using the SAS procedure Proc Plan. The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo. Patients were followed up for 8 weeks (all patients) and up to 76 weeks (patients with no viral rebound and excluding those who were randomised to the placebo group) after randomisation. The primary objective was safety and tolerability of RG-101. This trial was registered with EudraCT, number 2013-002978-49. FINDINGS: Between June 4, 2014, and Oct 27, 2014, we enrolled 32 patients with chronic HCV genotype 1 (n=16), 3 (n=10), or 4 (n=6) infections. In the first cohort, 14 patients were randomly assigned to receive 2 mg/kg RG-101 and two patients were randomly assigned to receive placebo, and in the second cohort, 14 patients were randomly assigned to receive 4 mg/kg RG-101 and two patients were randomly assigned to receive placebo. Overall, 26 of the 28 patients dosed with RG-101 reported at least one treatment-related adverse event. At week 4, the median viral load reduction from baseline was 4·42 (IQR 3·23-5·00) and 5·07 (4·19-5·35) log10 IU/mL in patients dosed with 2 mg/kg RG-101 or 4 mg/kg RG-101. Three patients had undetectable HCV RNA levels 76 weeks after a single dose of RG-101. Viral rebound at or before week 12 was associated with the appearance of resistance associated substitutions in miR-122 binding regions in the 5' UTR of the HCV genome. INTERPRETATION: This study showed that one administration of 2 mg/kg or 4 mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122oligonucleotide, was well tolerated and resulted in substantial viral load reduction in all treated patients within 4 weeks, and sustained virological response in three patients for 76 weeks. FUNDING: Regulus Therapeutics, Inc.
Authors: Ivan Zlatev; Adam Castoreno; Christopher R Brown; June Qin; Scott Waldron; Mark K Schlegel; Rohan Degaonkar; Svetlana Shulga-Morskaya; Huilei Xu; Swati Gupta; Shigeo Matsuda; Akin Akinc; Kallanthottathil G Rajeev; Muthiah Manoharan; Martin A Maier; Vasant Jadhav Journal: Nat Biotechnol Date: 2018-05-14 Impact factor: 54.908
Authors: Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua Journal: Drug Deliv Transl Res Date: 2018-02 Impact factor: 4.617
Authors: Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney Journal: Chem Rev Date: 2018-01-11 Impact factor: 60.622
Authors: Sheetal Trivedi; Satyapramod Murthy; Himanshu Sharma; Alex S Hartlage; Arvind Kumar; Sashi V Gadi; Peter Simmonds; Lokendra V Chauhan; Troels K H Scheel; Eva Billerbeck; Peter D Burbelo; Charles M Rice; W Ian Lipkin; Kurt Vandegrift; John M Cullen; Amit Kapoor Journal: Hepatology Date: 2018-05-21 Impact factor: 17.425